NextGen Bioscience, Inc.

NextGen Bioscience, Inc.

April 17, 2008 06:30 ET

NextGen and Oxon Life Science Explore Opportunity for Scientific Collaboration

LONDON, UNITED KINGDOM--(Marketwire - April 17, 2008) - NextGen Bioscience, Inc. ("NextGen") (PINK SHEETS:NXGB), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has entered into discussion about collaboration with Oxon Life Science ("Oxon"), from whom it has recently acquired use, commercialisation and ownership rights of a patent application for the treatment of cancer, regarding the development of the latest stem cell technology that NXGB has acquired from Oxon in that transaction.

NextGen CEO, Konstantinos Kardiasmenos, stated, "NextGen is excited about the possibility of close collaboration with Oxon. NextGen's proprietary technology, which we have acquired from Oxon, has the potential to treat breast cancer by more precisely targeting the cancer cells."

About NextGen Bioscience Inc.

NextGen is positioning itself as the world's leading bioscience company in the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

Statements about NextGen's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. NextGen's actual results could differ materially from expected results. NextGen undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.

For more information about NextGen Bioscience Inc., or to schedule an interview with Mr. Kardiasmenos, please contact Investor Relations at +44 20 7247 8186 or

Contact Information